Literature DB >> 30890514

[Correlation of lipoprotein(a) with clinical stability and severity of coronary artery lesions in patients with coronary artery disease].

Yusheng Ma1, Jiahuan Rao1, Jieni Long1, Lilong Lin1, Jichen Liu1, Zhigang Guo1.   

Abstract

OBJECTIVE: To analyze the correlation of lipoprotein(a) [Lp(a)] with the clinical stability and severity of coronary artery stenosis in patients with coronary artery disease (CAD).
METHODS: A total of 531 patients undergoing coronary angiography in Nanfang Hospital between January, 2013 and December, 2016 were enrolled in this study. At the cutoff Lp(a) concentration of 300 mg/L, the patients were divided into high Lp(a) group (n=191) and low Lp(a) group (n=340). In each group, the patients with an established diagnosis of CAD based on coronary angiography findings were further divided into stable angina pectoris (SAP) group and acute coronary syndrome (ACS) group. The correlation between the severity of coronary artery stenosis and Lp(a) was evaluated.
RESULTS: The patients in high and low Lp(a) groups showed no significant differences in age, gender, body mass index, smoking status, hypertension, or diabetes (P>0.05). Multivariate logistic regression analysis revealed that age, gender, and serum levels of low-density lipoprotein cholesterol (LDL-C) and Lp(a) were independent risk factors for CAD in these patients. A high Lp(a) level was associated with an increased risk of CAD (OR=2.443, 95%CI: 1.205-4.951, P=0.013). The patients with a high Lp(a) level were at a significantly higher risk of CAD than those with a low Lp(a) level irrespective of a low or high level of LDL-C (P=0.006 and 0.020). In the patients with CAD, the ACS group had a significantly higher Lp(a) level than the SAP group (P < 0.001); the proportion of the patients with high Gensini scores was significantly greater in high Lp(a) group than in low Lp(a) group (17.3% vs 5.6%, P=0.026), and a linear relationship was found between Lp(a) level and Gensini score (R=0.130, P=0.006).
CONCLUSIONS: Serum level of Lp(a) is an independent risk factor for CAD, and an increased Lp(a) is the residual risk for CAD. In patients with CAD, a high Lp(a) level is associated with the clinical instability and severity of coronary artery stenosis.

Entities:  

Keywords:  Gensini score; coronary artery disease; lipoprotein(a); low-density lipoprotein cholesterol; residual risk

Mesh:

Substances:

Year:  2019        PMID: 30890514      PMCID: PMC6765636          DOI: 10.12122/j.issn.1673-4254.2019.02.17

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  23 in total

1.  Pathological phenotypes of LDL particles.

Authors:  Ulrich Laufs; Oliver Weingärtner
Journal:  Eur Heart J       Date:  2018-07-14       Impact factor: 29.983

2.  2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).

Authors:  Christopher P Cannon; Ralph G Brindis; Bernard R Chaitman; David J Cohen; J Thomas Cross; Joseph P Drozda; Francis M Fesmire; Dan J Fintel; Gregg C Fonarow; Keith A Fox; Darryl T Gray; Robert A Harrington; Karen A Hicks; Judd E Hollander; Harlan Krumholz; Darwin R Labarthe; Janet B Long; Alice M Mascette; Connie Meyer; Eric D Peterson; Martha J Radford; Matthew T Roe; James B Richmann; Harry P Selker; David M Shahian; Richard E Shaw; Sharon Sprenger; Robert Swor; James A Underberg; Frans Van de Werf; Bonnie H Weiner; William S Weintraub
Journal:  Crit Pathw Cardiol       Date:  2013-06

3.  Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.

Authors:  Matthew C Weiss; Jeffrey S Berger; Eugenia Gianos; Edward Fisher; Arthur Schwartzbard; James Underberg; Howard Weintraub
Journal:  J Clin Lipidol       Date:  2017-07-22       Impact factor: 4.766

4.  Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Authors:  Daniel Gaudet; Gerald F Watts; Jennifer G Robinson; Pascal Minini; William J Sasiela; Jay Edelberg; Michael J Louie; Frederick J Raal
Journal:  Am J Cardiol       Date:  2016-09-29       Impact factor: 2.778

5.  LDL-cholesterol Predicts a First CHD Event in Senior Citizens, Especially So in Those With Elevated Lipoprotein(a): Dubbo Study of the Elderly.

Authors:  Leon A Simons; Judith Simons; Yechiel Friedlander; John McCallum
Journal:  Heart Lung Circ       Date:  2017-05-17       Impact factor: 2.975

6.  Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States.

Authors:  Steve Varvel; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

7.  Lipoprotein (a) as a Marker for Predicting the Presence and Severity of Coronary Artery Disease in Untreated Chinese Patients Undergoing Coronary Angiography.

Authors:  Di Sun; Xi Zhao; Sha Li; Yan Zhang; Na Qiong Wu; Cheng Gang Zhu; Yuan Lin Guo; Ying Gao; Ping Qing; Geng Liu; Qian Dong; Jian Jun Li
Journal:  Biomed Environ Sci       Date:  2018-04       Impact factor: 3.118

8.  Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.

Authors:  Christoph Waldeyer; Nataliya Makarova; Tanja Zeller; Renate B Schnabel; Fabian J Brunner; Torben Jørgensen; Allan Linneberg; Teemu Niiranen; Veikko Salomaa; Pekka Jousilahti; John Yarnell; Marco M Ferrario; Giovanni Veronesi; Paolo Brambilla; Stefano G Signorini; Licia Iacoviello; Simona Costanzo; Simona Giampaoli; Luigi Palmieri; Christa Meisinger; Barbara Thorand; Frank Kee; Wolfgang Koenig; Francisco Ojeda; Jukka Kontto; Ulf Landmesser; Kari Kuulasmaa; Stefan Blankenberg
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

9.  Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns.

Authors:  Gertraud Erhart; Claudia Lamina; Terho Lehtimäki; Pedro Marques-Vidal; Mika Kähönen; Peter Vollenweider; Olli T Raitakari; Gérard Waeber; Barbara Thorand; Konstantin Strauch; Christian Gieger; Thomas Meitinger; Annette Peters; Florian Kronenberg; Stefan Coassin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-22       Impact factor: 8.311

10.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

View more
  1 in total

1.  The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels.

Authors:  Weifeng Xu; Haiwang Guan; Da Gao; Zicheng Wang; Yanna Ba; Hao Yang; Wenjun Shen; Jiangfang Lian; Jianqing Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-12       Impact factor: 3.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.